Literature DB >> 13872499

Tetrabenacine treatment in persisting dyskinesia caused by psychopharmaca.

E BRANDRUP.   

Abstract

Entities:  

Keywords:  MOVEMENT DISORDERS/etiology; PSYCHOPHARMACOLOGY/complications; TRANQUILIZING AGENTS/therapy

Mesh:

Substances:

Year:  1961        PMID: 13872499     DOI: 10.1176/ajp.118.6.551

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


× No keyword cloud information.
  6 in total

Review 1.  Tardive Dyskinesia Associated with Atypical Antipsychotics: Prevalence, Mechanisms and Management Strategies.

Authors:  Katharina Stegmayer; Sebastian Walther; Peter van Harten
Journal:  CNS Drugs       Date:  2018-02       Impact factor: 5.749

Review 2.  Orofacial dyskinesia. Clinical features, mechanisms and drug therapy.

Authors:  R M Kobayashi
Journal:  West J Med       Date:  1976-10

3.  Treatment of involuntary movement disorders with tetrabenazine.

Authors:  M Swash; A H Roberts; H Zakko; K W Heathfield
Journal:  J Neurol Neurosurg Psychiatry       Date:  1972-04       Impact factor: 10.154

4.  Thiopropazate hydrochloride in persistent dyskinesia.

Authors:  K Singer; M N Cheng
Journal:  Br Med J       Date:  1971-10-02

5.  Tetrabenazine (Nitoman) therapy of chronic spontaneous oral dyskinesia. A video- and EMG-controlled study.

Authors:  M Bartels; E Zeller
Journal:  Eur Arch Psychiatry Neurol Sci       Date:  1984

6.  Reserpine and alpha-methyldopa in the treatment of tardive dyskinesia.

Authors:  C C Huang; R I Wang; A Hasegawa; L Alverno
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.